Skip to main content
Book cover

Antimicrobial Drug Resistance

Mechanisms of Drug Resistance, Volume 1

  • Book
  • © 2017

Overview

  • New chapters and authors on recent developments in drug resistance
  • Expertise from over 197 international professionals in the field
  • Discusses drug resistance genes and the implementation of genomic data
  • Additional three new topics regarding increasingly important public health issues
  • Includes supplementary material: sn.pub/extras

This is a preview of subscription content, log in via an institution to check access.

Access this book

eBook USD 299.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 379.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (48 chapters)

  1. General Overview

  2. General Mechanisms of Drug Resistance

  3. Bacterial Drug Resistance: Mechanisms

Keywords

About this book

The two volumes included in Antimicrobial Drug Resistance, Second Edition is an updated, comprehensive and multidisciplinary reference covering the area of antimicrobial drug resistance in bacteria, fungi, viruses, and parasites from basic science, clinical, and epidemiological perspectives. This newly revised compendium reviews the most current research and development on drug resistance while still providing the information in the accessible format of the first edition. The first volume, Antimicrobial Drug Resistance: Mechanisms of Drug Resistance, is dedicated to the biological basis of drug resistance and effective avenues for drug development. With the emergence of more drug-resistant organisms, the approach to dealing with the drug resistance problem must include the research of different aspects of the mechanisms of bacterial resistance and the dissemination of resistance genes as well as research utilizing new genomic information. These approaches will permit the design of novel strategies to develop new antibiotics and preserve the effectiveness of those currently available. The second volume, Antimicrobial Drug Resistance: Clinical and Epidemiological Aspects, is devoted to the clinical aspects of drug resistance. Although there is evidence that restricted use of a specific antibiotic can be followed by a decrease in drug resistance to that agent, drug resistance control is not easily achieved. Thus, the infectious diseases physician requires input from the clinical microbiologist, antimicrobial stewardship personnel, and infection control specialist to make informed choices for the effective management of various strains of drug-resistant pathogens in individual patients. This 2-volume set is an important reference for students in microbiology, infectious diseases physicians, medical students, basic scientists, drug development researchers, microbiologists, epidemiologists, and public health practitioners.

Editors and Affiliations

  • Treiber Therapeutics, Cambridge, USA

    Douglas L. Mayers

  • Wayne State University School of Medicine, Detroit Medical Center, Detroit, USA

    Jack D. Sobel

  • Centre de recherche en Infectiologie, University of Laval, Quebec City, Canada

    Marc Ouellette

  • Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, USA

    Keith S. Kaye

  • Infection Control and Prevention Unit of Infectious Diseases, Assaf Harofeh Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel

    Dror Marchaim

About the editors

Douglas L. Mayers is an infectious diseases specialist and is currently Chief Medical Officer (CMO) at Cocrystal Pharma. Dr. Mayers received his M.D. from University of Pennsylvania and has over 20 years of medical and clinical development experience spanning all phases of global clinical research and development and commercialization. He has worked with the United States Army Medical Research Institute of Infectious Diseases to discover and develop drugs against the Ebola virus. He has also served as the Head of HIV Clinical Studies Program and Department of HIV Disease Prevention at the Walter Reed Army Institute of Research and Naval Medical Research Institute. Previously, he was the Chief Medical Officer and Executive Vice President at Idenix Pharmaceuticals, where he directed the Infectious Disease programs and led numerous regulatory filings globally, including successful advancement of several anti-HCV candidates to the clinical phase. Prior to Idenix, he was the International Head/Vice President of the Virology Therapeutic Area at Boehringer Ingelheim where he led Phase 1 through 4 clinical studies for HIV and hepatitis programs. In addition to his extensive expertise in the industry and in research, Dr. Mayers is well-known in the academic sphere and is the author of over 95 peer-reviewed publications and book chapters.

Bibliographic Information

  • Book Title: Antimicrobial Drug Resistance

  • Book Subtitle: Mechanisms of Drug Resistance, Volume 1

  • Editors: Douglas L. Mayers, Jack D. Sobel, Marc Ouellette, Keith S. Kaye, Dror Marchaim

  • DOI: https://doi.org/10.1007/978-3-319-46718-4

  • Publisher: Springer Cham

  • eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)

  • Copyright Information: Springer International Publishing AG 2017

  • Hardcover ISBN: 978-3-319-46716-0Published: 07 July 2017

  • Softcover ISBN: 978-3-319-83571-6Published: 12 June 2018

  • eBook ISBN: 978-3-319-46718-4Published: 19 June 2017

  • Edition Number: 2

  • Number of Pages: XXI, 773

  • Number of Illustrations: 103 b/w illustrations, 61 illustrations in colour

  • Topics: Drug Resistance, Infectious Diseases

Publish with us